Difference between revisions of "Paired box gene 8"
Jump to navigation
Jump to search
m (vauthors) |
|||
| (15 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{ Infobox immunostain | {{ Infobox immunostain | ||
| Name = {{PAGENAME}} | | Name = {{PAGENAME}} | ||
| Image = | | Image = Poorly differentiated carcinoma -- PAX8 - intermed mag.jpg | ||
| Width = | | Width = | ||
| Caption = | | Caption = PAX8 staining in a poorly differentiated [[carcinoma]]. | ||
| Abbrev = PAX8 | | Abbrev = PAX8 | ||
| Synonyms = | | Synonyms = | ||
| Line 10: | Line 10: | ||
| Use = RCC versus other, gynecologic tract malignancy versus other | | Use = RCC versus other, gynecologic tract malignancy versus other | ||
| Subspecial = [[gynecologic pathology]], [[genitourinary pathology]] | | Subspecial = [[gynecologic pathology]], [[genitourinary pathology]] | ||
| Pattern = | | Pattern = nuclear stain | ||
| Positive = [[renal cell carcinoma]]s, [[renal oncocytoma]], thyroid tumours, [[serous carcinoma]], [[endometrial carcinoma]]s | | Positive = [[renal cell carcinoma]]s, [[renal oncocytoma]], thyroid tumours, [[serous carcinoma]], [[endometrial carcinoma]]s | ||
| Negative = | | Negative = | ||
| Line 24: | Line 24: | ||
*Nonserous epithelial [[ovarian tumours|ovarian neoplasms]] ~ 70%.<ref name=pmid21552115/> | *Nonserous epithelial [[ovarian tumours|ovarian neoplasms]] ~ 70%.<ref name=pmid21552115/> | ||
*[[Endometrial carcinoma]]s ~ 98%.<ref name=pmid21552115/> | *[[Endometrial carcinoma]]s ~ 98%.<ref name=pmid21552115/> | ||
*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal | last1 = Sangoi | first1 = AR. | last2 = Ohgami | first2 = RS. | last3 = Pai | first3 = RK. | last4 = Beck | first4 = AH. | last5 = McKenney | first5 = JK. | last6 = Pai | first6 = RK. | title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. | journal = Mod Pathol | volume = 24 | issue = 3 | pages = 412-24 | month = Mar | year = 2011 | doi = 10.1038/modpathol.2010.176 | PMID = 20890270 }}</ref> | |||
**Can help differentiate from lung NETs. | |||
*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal |authors=Weissferdt A, Moran CA |title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis |journal=Am. J. Surg. Pathol. |volume=35 |issue=9 |pages=1305–10 |date=September 2011 |pmid=21836478 |doi=10.1097/PAS.0b013e3182260735 |url=}}</ref> | |||
===May be positive=== | |||
*Peritoneal [[malignant mesothelioma]] (5 +ve of 27<ref name=pmid28877056>{{cite journal |authors=Chapel DB, Husain AN, Krausz T, McGregor SM |title=PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma |journal=Am. J. Surg. Pathol. |volume=41 |issue=12 |pages=1675–1682 |date=December 2017 |pmid=28877056 |doi=10.1097/PAS.0000000000000935 |url=}}</ref>). | |||
==Negative staining== | |||
[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg|thumb|right|300px|Negative PAX8 staining in a lymphoma.]] | |||
*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>). | |||
*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal |authors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F |title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas |journal=Mod. Pathol. |volume=25 |issue=2 |pages=231–6 |date=February 2012 |pmid=22037256 |doi=10.1038/modpathol.2011.162 |url=}}</ref> | |||
*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal | last1 = Tacha | first1 = D. | last2 = Zhou | first2 = D. | last3 = Cheng | first3 = L. | title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. | journal = Appl Immunohistochem Mol Morphol | volume = 19 | issue = 4 | pages = 293-9 | month = Jul | year = 2011 | doi = 10.1097/PAI.0b013e3182025f66 | PMID = 21285870 }}</ref> | |||
*Salivary gland and salivary gland tumours.<ref>{{cite journal |authors=Butler RT, Alderman MA, Thompson LD, McHugh JB |title=Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms |journal=Head Neck Pathol |volume=9 |issue=1 |pages=47–50 |date=March 2015 |pmid=24771139 |pmc=4382472 |doi=10.1007/s12105-014-0546-4 |url=}}</ref> | |||
==See also== | ==See also== | ||
Latest revision as of 17:13, 25 March 2021
| Paired box gene 8 | |
|---|---|
| Immunostain in short | |
 PAX8 staining in a poorly differentiated carcinoma. | |
| Abbreviation | PAX8 |
| Use | RCC versus other, gynecologic tract malignancy versus other |
| Subspeciality | gynecologic pathology, genitourinary pathology |
| Normal staining pattern | nuclear stain |
| Positive | renal cell carcinomas, renal oncocytoma, thyroid tumours, serous carcinoma, endometrial carcinomas |
Paired box gene 8, commonly known by the abbreviation PAX8, is a commonly used immunostain in gynecologic pathology and genitourinary pathology.
Tumours with positive staining
- Thyroid tumours ~ 90%.[1]
- Renal cell carcinomas ~ 90%.[1]
- Renal oncocytomas ~ 80%.[1]
- High-grade ovarian serous carcinomas ~ 99%.[1]
- Nonserous epithelial ovarian neoplasms ~ 70%.[1]
- Endometrial carcinomas ~ 98%.[1]
- Pancreatic neuroendocrine tumour ~ 74%.[2]
- Can help differentiate from lung NETs.
- Epithelial component of thymic tumors 77-100% depending on sub-type[1][3]
May be positive
- Peritoneal malignant mesothelioma (5 +ve of 27[4]).
Negative staining
- Urothelial carcinoma - can be positive (3 positive/18 bladder tumours[1]).
- Lymphoma (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with PAX5)[5]
- Malignant melanoma.[6]
- Salivary gland and salivary gland tumours.[7]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Laury, AR.; Perets, R.; Piao, H.; Krane, JF.; Barletta, JA.; French, C.; Chirieac, LR.; Lis, R. et al. (Jun 2011). "A comprehensive analysis of PAX8 expression in human epithelial tumors.". Am J Surg Pathol 35 (6): 816-26. doi:10.1097/PAS.0b013e318216c112. PMID 21552115.
- ↑ Sangoi, AR.; Ohgami, RS.; Pai, RK.; Beck, AH.; McKenney, JK.; Pai, RK. (Mar 2011). "PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.". Mod Pathol 24 (3): 412-24. doi:10.1038/modpathol.2010.176. PMID 20890270.
- ↑ Weissferdt A, Moran CA (September 2011). "Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis". Am. J. Surg. Pathol. 35 (9): 1305–10. doi:10.1097/PAS.0b013e3182260735. PMID 21836478.
- ↑ Chapel DB, Husain AN, Krausz T, McGregor SM (December 2017). "PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma". Am. J. Surg. Pathol. 41 (12): 1675–1682. doi:10.1097/PAS.0000000000000935. PMID 28877056.
- ↑ Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F (February 2012). "N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas". Mod. Pathol. 25 (2): 231–6. doi:10.1038/modpathol.2011.162. PMID 22037256.
- ↑ Tacha, D.; Zhou, D.; Cheng, L. (Jul 2011). "Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.". Appl Immunohistochem Mol Morphol 19 (4): 293-9. doi:10.1097/PAI.0b013e3182025f66. PMID 21285870.
- ↑ Butler RT, Alderman MA, Thompson LD, McHugh JB (March 2015). "Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms". Head Neck Pathol 9 (1): 47–50. doi:10.1007/s12105-014-0546-4. PMC 4382472. PMID 24771139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382472/.